Complexed and total PSA in patients with benign prostatic hyperplasia and prostate cancer

References

• Wang MC, Valenzuela LA, Murphy GP, Chu TM. Purification of a human prostate specific antigen. Invest Urol 1979; 17: 159–63.
   Google Scholar
• Lilja H. A kallikrein-like serine protease in prostatic fluid cleaves the predominant seminal vesicle protein. J Clin Invest 1985; 76: 1899–903.
   Google Scholar
• Oesterling JE, Jacobsen SJ, Klee GG et al. Free, complexed and total serum prostate specific antigen: the establishment of appropriate reference ranges for their concentrations and ratios. J Urol 1995; 154: 1090–5.
   Google Scholar
• Catalona WJ, Partin AW, Slawin KM et al. Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: a prospective multicenter clinical trial. JAMA 1998; 279: 1542–7.
   Google Scholar
• Paus E, Nustad K, Bormer OP. Epitope mapping and affinity estimation of 83 antibodies against prostate-specific antigen. Tumour Biol 1999; 20 (Suppl 1): 52–69.
   Google Scholar
• Nurmikko P, Pettersson K, Piironen T, Hugosson J, Lilja H. Discrimination of prostate cancer from benign disease by plasma measurement of intact, free prostate-specific antigen lacking an internal cleavage site at Lys145–Lys146. Clin Chem 2001; 47: 1415–23.
   Google Scholar
• Jung K, Brux B, Lein M et al. Molecular forms of prostate-specific antigen in malignant and benign prostatic tissue: biochemical and diagnostic implications. Clin Chem 2000; 46: 47–54.
   Google Scholar
• Hara I, Miyake H, Hara S et al. Significance of prostate-specific antigen–alpha(1)-antichymotrypsin complex for diagnosis and staging of prostate cancer. Jpn J Clin Oncol 2001; 31: 506–9.
   Google Scholar
• Jung K, Stephan C, Elgeti U et al. Molecular forms of prostate-specific antigen in serum with concentrations of total prostate-specific antigen less than 4 µg/L: are they useful tools for early detection and screening of prostate cancer? Int J Cancer 2001; 93: 759–65.
   Google Scholar
• Catalona WJ, Smith DS, Ratliff TL et al. Measurement of PSA in serum as a screening test for prostate cancer. N Engl J Med 1991; 324: 1156–61.
   Google Scholar
• Emiliozzi P, Longhi S, Scarpone P, Pansadoro A, DePaula F, Pansadoro V. The value of a single biopsy with 12 transperineal cores for detecting prostate cancer in patients with elevated prostate specific antigen. J Urol 2001; 166: 845–50.
   Google Scholar
• Catalona WJ, Partin AW, Finlay JA et al. Use of percentage of free prostate-specific antigen to identify men at high risk of prostate cancer when PSA levels are 2.51 to 4 ng/mL and digital rectal examination is not suspicious for prostate cancer: an alternative model. Urology 1999; 54: 220–4.
   Google Scholar
• Carsten S, Klaas M, Müller C et al. Interchangeability of measurements of total and free prostate-specific antigen in serum with 5 frequently used assay combinations: an update. Clin Chem 2006; 52: 59–64.
   Google Scholar
• Boring CC, Squires TS, Tong T, Montgomery S. Cancer statistics. CA Cancer J Clin 1994; 44 (1): 7–26.
   Google Scholar
• Ramzi S, Vinay K, Stanley L. In: Robbins Pathologic Basis of Disease. 5th edn. London: Saunders, 1995: 1025–30.
   Google Scholar
• Al Hamdan NA, Al-Zahrani A, Harper DM, Koricch O, Bazarbashi S. National Cancer Registry 1994 Report, Ministry of Health, Kingdom of Saudi Arabia. In: Cancer Incidence in Saudi Arabia. May 1996: 25–6.
   Google Scholar
• Mansoor I. Pattern of prostatic diseases in Saudi Arabia. Internet J Pathol 2003; 2 (2).
   Google Scholar
• Ten most common cancers among Saudis by sex. National Cancer Registry, King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia, 2002 (www.kfsprc.org).
   Google Scholar
• Ezzat A, Raja M, Te O, Michels D, Bazarbashi S. Frequency and distribution of 22,836 adult cancer cases referred to King Faisal Specialist Hospital and Research Centre. Ann Saudi Med 1996: 16: 152–8.
   Google Scholar
• Al-Khudair W, Mansi M, Fatthalla A. Prostate cancer: a retrospective study. Paper presented at the 10th Saudi Urological Conference, Riyadh, Saudi Arabia.
   Google Scholar
• Sehai ZE. Cancer in Saudi Arabia. Ann Saudi Med 1989; 9: 55–63.
   Google Scholar
• Ibrahim EM, Al-Muhanna FA et al. Public knowledge, misperceptions and attitudes about cancer in Saudi Arabia. Ann Saudi Med 1991; 11: 518–23.
   Google Scholar
• Froehner M, Hakenberg OW, Koch R, Schmidt U, Meye A, Wirth MP. Comparison of the clinical value of complexed PSA and total PSA in the discrimination between benign prostatic hyperplasia and prostate cancer. Urol Int 2006; 76 (1): 27–30.
   Google Scholar
• Loeb S, Catalon W. Prostate-specific antigen in clinical practice. Cancer Lett 2007; 249 (1): 30–9.
   Google Scholar
• Brawer MK, Cheli CD, Neaman IE et al. Complexed prostate-specific antigen provides significant enhancement of specificity compared with total prostate specific antigen for detecting prostate cancer. J Urol 2000; 163 (5): 1476–80.
   Google Scholar
• Catalona WJ, Richie JP, Ahmann FR et al. Comparison of digital rectal examination and serum prostate specific antigen in the early detection of prostate cancer: results of a multicenter clinical trial of 6,630 men. J Urol 1994; 151 (5): 1283–90.
   Google Scholar
• Maeda H, Arai Y, Aoki Y, Okubo K, Okada T,Maekawa S. Complexed prostate-specific antigen and its volume indexes in the detection of prostate cancer. Urology 1999; 54 (2): 225–8.
   Google Scholar
• Okegawa T, Noda H, Nutahara K, Higashihara E. Comparison of two investigative assays for the complexed prostate-specific antigen in total prostate-specific antigen between 4.1 and 10.0 ng/mL. Urology 2000; 55 (5): 700–4.
   Google Scholar
• Jung K, Elgeti U, Lein M et al. Ratio of free or complexed prostate-specific antigen (PSA) to total PSA: which ratio improves differentiation between benign prostatic hyperplasia and prostate cancer? Clin Chem 2000; 46 (1): 55–62.
   Google Scholar
• Stephan C, Kramer J, Meyer HA et al. Different prostate-specific antigen assays give different results on the same blood sample: an obstacle to recommending uniform limits for prostate biopsies. BJU Int 2007; 99 (6): 1427–31.
   Google Scholar
• Kort SA, Martens F, Vanpoucke H, van Duijnhoven HL, Blankenstein MA. Comparison of 6 automated assays for total and free prostate-specific antigen with special reference to their reactivity toward the WHO 96/670 reference preparation. Clin Chem 2006; 52 (8): 1568–74.
   Google Scholar
• Tarhan F, Orcun A, Kucukercan I, Camursoy N, Kuyumcuoglu U. Effect of hemodialysis on serum complexed prostate-specific antigen levels. Scand J Urol Nephrol 2007; 41 (5): 382–6.
   Google Scholar
• Raaijmakers R, de Vries SH, Blijenberg BG et al. hK2 and free PSA, a prognostic combination in predicting minimal prostate cancer in screen-detected men within the PSA range 4–10 ng/mL. Eur Urol 2007; 52 (5): 1297–9.
   Google Scholar
• Shariat SF, Roehrborn CG, McConnell JD et al. Association of the circulating levels of the urokinase system of plasminogen activation with the presence of prostate cancer and invasion, progression and metastasis. J Clin Oncol 2007; 25 (4): 347–8.
   Google Scholar
• Leman ES, Cannon GW, Trock BJ et al. EPCA-2: a highly specific serum marker for prostate cancer. Urology 2007; 69 (4): 714–20.
   Google Scholar
• Zhang L, Wang CY, Yang R et al. Real-time quantitative RT-PCR assay of prostate-specific antigen and prostate-specific membrane antigen in peripheral blood for detection of prostate cancer micrometastasis. Urol Oncol 2008; 26 (6): 634–40.
   Google Scholar
• Hirano D, Minei S, Sugimoto S et al. Implications of circulating chromogranin A in prostate cancer. Scand J Urol Nephrol 2007; 41 (4): 297–301.
   Google Scholar